These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 26731855

  • 1. [Novel oral anticoagulants--issues in clinical practice].
    Hohmann C, Neumann-Haefelin T, Radziwill R, Benöhr P.
    Med Monatsschr Pharm; 2015 Oct; 38(10):374-85; quiz 387-8. PubMed ID: 26731855
    [Abstract] [Full Text] [Related]

  • 2. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
    Bass AR.
    Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
    [Abstract] [Full Text] [Related]

  • 3. Anticoagulants: What is new and what is the standard?
    Lesko LJ.
    Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
    [Abstract] [Full Text] [Related]

  • 4. [From heparin to apixaban: anticoagulants cut both ways?].
    Hartung K, Meyer F, Bock F, Isermann B.
    Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104
    [Abstract] [Full Text] [Related]

  • 5. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G, Becattini C, Franco L.
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [Abstract] [Full Text] [Related]

  • 6. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B, Roca M.
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [Abstract] [Full Text] [Related]

  • 7. Italian intersociety consensus on DOAC use in internal medicine.
    Prisco D, Ageno W, Becattini C, D'Angelo A, Davì G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI (Italian Society of Internal Medicine), FADOI (Federation of Associations of Hospital Doctors on Internal Medicine), SISET (Italian Society for the Study of Haemostasis and Thrombosis).
    Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
    [Abstract] [Full Text] [Related]

  • 8. Practical recommendations on incorporating new oral anticoagulants into routine practice.
    Randhawa J, Thiruchelvam N, Ghobrial M, Spiro T, Clark B, Haddad A, Daw H.
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):675-83. PubMed ID: 25658892
    [Abstract] [Full Text] [Related]

  • 9. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M, Lip GY.
    Expert Opin Pharmacother; 2015 Oct; 16(11):1573-6. PubMed ID: 26077323
    [Abstract] [Full Text] [Related]

  • 10. The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
    Papadopoulos DV, Kostas-Agnantis I, Gkiatas I, Tsantes AG, Ziara P, Korompilias AV.
    Eur J Orthop Surg Traumatol; 2017 Jul; 27(5):573-582. PubMed ID: 28314985
    [Abstract] [Full Text] [Related]

  • 11. Reversal of anticoagulants: an overview of current developments.
    Greinacher A, Thiele T, Selleng K.
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [Abstract] [Full Text] [Related]

  • 12. [The latest recommendations on the use of new oral anticoagulants in routine practice].
    Witkowski M, Witkowska M, Smolewski P.
    Postepy Hig Med Dosw (Online); 2016 Feb 08; 70():43-55. PubMed ID: 26864063
    [Abstract] [Full Text] [Related]

  • 13. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
    Krumme AA, Pawar A, Schneeweiss S, Glynn RJ, Choudhry NK, Kulldorff M, Ortiz AS, Avorn J, Gagne JJ.
    J Comp Eff Res; 2018 Jan 08; 7(1):57-66. PubMed ID: 29264930
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.
    Krejczy M, Harenberg J, Wehling M, Obermann K, Lip GY.
    Biomed Res Int; 2015 Jan 08; 2015():876923. PubMed ID: 25853142
    [Abstract] [Full Text] [Related]

  • 15. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
    De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Ricci F, Sibbing D, Siegbahn A, Storey RF, Ten Berg J, Verheugt FW, Weitz JI.
    Thromb Haemost; 2016 Apr 08; 115(4):685-711. PubMed ID: 26952877
    [Abstract] [Full Text] [Related]

  • 16. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M.
    J Med Econ; 2015 Jun 08; 18(6):399-409. PubMed ID: 25586203
    [Abstract] [Full Text] [Related]

  • 17. Direct oral anticoagulants: a guide for daily practice.
    Fontana P, Robert-Ebadi H, Bounameaux H, Boehlen F, Righini M.
    Swiss Med Wkly; 2016 Jun 08; 146():w14286. PubMed ID: 26964028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI, Quinlan DJ, Eikelboom JW.
    Annu Rev Med; 2011 Jun 08; 62():41-57. PubMed ID: 21226611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.